tbuckley/cabot-search huggingface dataset:
Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial
Authors: Erin L. Van Blarigan, Sui Zhang, Fang-Shu Ou, Alan Venlo, Kimmie Ng, Chloe Atreya, Katherine Van Loon, Donna Niedzwiecki, Edward Giovannucci, Eric G. Wolfe, Heinz-Josef Lenz, Federico Innocenti, Bert H. O’Neil, James E. Shaw, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Eileen M. O’Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt
Journal: JAMA Network Open (2020)

Diet has been associated with survival in patients with stage I to III colorectal cancer, but data on patients with metastatic colorectal cancer are limited.To examine the association between diet quality and overall survival among individuals with metastatic colorectal cancer.This was a prospective cohort study of patients with metastatic colorectal cancer who were enrolled in the Cancer and Leukemia Group B (Alliance) and Southwest Oncology Group 80405 trial between October 27, 2005, and February 29, 2012, and followed up through January 2018.Participants completed a validated food frequency questionnaire within 4 weeks after initiation of first-line treatment for metastatic colorectal cancer. Diets were categorized according to the Alternative Healthy Eating Index (AHEI), Alternate Mediterranean Diet (AMED) score, Dietary Approaches to Stop Hypertension (DASH) score, and Western and prudent dietary patterns derived using principal component analysis. Participants were categorized into sex-specific quintiles.Multivariable hazard ratios (HRs) and 95% CIs for overall survival.In this cohort study of 1284 individuals with metastatic colorectal cancer, the median age was 59 (interquartile range [IQR]: 51-68) years, median body mass index was 27.2 (IQR, 24.1-31.4), 521 (41%) were female, and 1102 (86%) were White. There were 1100 deaths during a median follow-up of 73 months (IQR, 64-87 months). We observed an inverse association between the AMED score and risk of death (HR quintile 5 vs quintile 1, 0.83; 95% CI, 0.67-1.04; P = .04 for trend), but the point estimates were not statistically significant. None of the other diet scores or patterns were associated with overall survival.In this prospective analysis of patients with metastatic colorectal cancer, diet quality assessed at initiation of first-line treatment for metastatic disease was not associated with overall survival.
Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Ajay Nooka, Hans C. Lee, Ashraf Z. Badros, Peter Voorhees, Malin Hultcrantz, Lionel Karlin, Bertrand Arnulf, Paul G. Richardson, Eric Zhi, January Baron, Trisha Piontek, Eric Lewis, Joanna Opalinska, Ira Gupta, Adam D. Cohen, Sagar Lonial
Journal: Blood (2020)
Frequency of IKZF1 Deletions in a Peruvian Population with B-Cell Acute Lymphoblastic Leukemia
Authors: Daniel J Enriquez, Rachel J. Mitchell, Krisztina Zuborne Alapi, Elizabeth Cervantes, Karina Cancino, Jhoysi Casas, Bryan Valcarcel, Gustavo Sandival, Juan C Haro, Cesar Samanez-Figari, Arturo Zapata, Juan L Garcia-Leon, Adele K. Fielding
Journal: Blood (2020)
Neutrophils in liver diseases: pathogenesis and therapeutic targets
Authors: Kai Liu, Fu-Sheng Wang, Ruonan Xu
Journal: Cellular and Molecular Immunology (2020)

Previously, it was assumed that peripheral neutrophils are a homogeneous population that displays antimicrobial functions. However, recent data have revealed that neutrophils are heterogeneous and are additionally involved in tissue damage and immune regulation. The phenotypic and functional plasticity of neutrophils has been identified in patients with cancer, inflammatory disorders, infections, and other diseases. Currently, neutrophils, with their autocrine, paracrine, and immune modulation functions, have been shown to be involved in liver diseases, including viral hepatitis, nonalcoholic steatohepatitis, alcoholic liver disease, liver fibrosis, cirrhosis, liver failure, and liver cancer. Accordingly, this review summarizes the role of neutrophils in liver diseases.
Immunomodulatory role of reactive oxygen species and nitrogen species during T cell-driven neutrophil-enriched acute and chronic cutaneous delayed-type hypersensitivity reactions
Authors: Roman Mehling, Johannes Schwenck, Christina Lemberg, Christoph Trautwein, Laimdota Zizmare, Daniela Kramer, Anne Müller, Birgit Fehrenbacher, Irene Gonzalez-Menendez, Leticia Quintanilla-Martinez, Katrin Schröder, Ralph P. Brandes, Martin Schaller, Wolfram Ruf, Martin Eichner, Kamran Ghoreschi, Martin Röcken, Bernd J. Pichler, Manfred Kneilling
Journal: Theranostics (2020)

Rationale: Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are important regulators of inflammation. The exact impact of ROS/RNS on cutaneous delayed-type hypersensitivity reaction (DTHR) is controversial. The aim of our study was to identify the dominant sources of ROS/RNS during acute and chronic trinitrochlorobenzene (TNCB)-induced cutaneous DTHR in mice with differently impaired ROS/RNS production. Methods: TNCB-sensitized wild-type, NADPH oxidase 2 (NOX2)- deficient (gp91phox-/-), myeloperoxidase-deficient (MPO-/-), and inducible nitric oxide synthase-deficient (iNOS-/-) mice were challenged with TNCB on the right ear once to elicit acute DTHR and repetitively up to five times to induce chronic DTHR. We measured ear swelling responses and noninvasively assessed ROS/RNS production in vivo by employing the chemiluminescence optical imaging (OI) probe L-012. Additionally, we conducted extensive ex vivo analyses of inflamed ears focusing on ROS/RNS production and the biochemical and morphological consequences. Results: The in vivo L-012 OI of acute and chronic DTHR revealed completely abrogated ROS/RNS production in the ears of gp91phox-/- mice, up to 90 % decreased ROS/RNS production in the ears of MPO-/- mice and unaffected ROS/RNS production in the ears of iNOS-/- mice. The DHR flow cytometry analysis of leukocytes derived from the ears with acute DTHR confirmed our in vivo L-012 OI results. Nevertheless, we observed no significant differences in the ear swelling responses among all the experimental groups. The histopathological analysis of the ears of gp91phox-/- mice with acute DTHRs revealed slightly enhanced inflammation. In contrast, we observed a moderately reduced inflammatory immune response in the ears of gp91phox-/- mice with chronic DTHR, while the inflamed ears of MPO-/- mice exhibited the strongest inflammation. Analyses of lipid peroxidation, 8-hydroxy-2'deoxyguanosine levels, redox related metabolites and genomic expression of antioxidant proteins revealed similar oxidative stress in all experimental groups. Furthermore, inflamed ears of wild-type and gp91phox-/- mice displayed neutrophil extracellular trap (NET) formation exclusively in acute but not chronic DTHR. Conclusions: MPO and NOX2 are the dominant sources of ROS/RNS in acute and chronic DTHR. Nevertheless, depletion of one primary source of ROS/RNS exhibited only marginal but conflicting impact on acute and chronic cutaneous DTHR. Thus, ROS/RNS are not a single entity, and each species has different properties at certain stages of the disease, resulting in different outcomes.
Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML
Authors: Frank Cichocki, Ryan Bjordahl, Karrune Woan, Zachary Davis, Greg Bonello, Sajid Mahmood, Paul Rogers, Moyar Q. Ge, Tom Lee, Martin Felices, Bruce Walcheck, Bruce R. Blazar, Bahram Valamehr, Jeffrey S. Miller
Journal: Blood (2020)
Synergistic Antitumor Effect and Mechanism of Chidamide Combined with Gemcitabine, Oxaliplatin or Zanubrutinib in Diffuse Large B-Cell Lymphoma
Authors: Qingqing Cai, Tianying Huang, Ning Su, Xiaolu Xu, Fengwei Wang, Yu Fang, Xiaopeng Tian, Jun Cai, Shuyun Ma, Yang Liang
Journal: Blood (2020)
A randomised controlled feasibility trial of E-health application supported care vs usual care after exacerbation of COPD: the RESCUE trial
Authors: Mal North, Simon Bourne, Ben Green, Anoop J. Chauhan, Tom Brown, Jonathan Winter, Tom Jones, Dan Neville, Alison Blythin, Alastair Watson, Matthew Johnson, David Culliford, Jack Elkes, Victoria Cornelius, Tom M. A. Wilkinson
Journal: npj Digital Medicine (2020)

Exacerbations of COPD are one of the commonest causes of admission and readmission to hospital. The role of digital interventions to support self-management in improving outcomes is uncertain. We conducted an open, randomised controlled trial of a digital health platform application (app) in 41 COPD patients recruited following hospital admission with an acute exacerbation. Subjects were randomised to either receive usual care, including a written self-management plan (n = 21), or the myCOPD app (n = 20) for 90 days. The primary efficacy outcome was recovery rate of symptoms measured by COPD assessment test (CAT) score. Exacerbations, readmission, inhaler technique quality of life and patient activation (PAM) scores were also captured by a blinded team. The app was acceptable in this care setting and was used by 17 of the 20 patients with sustained use over the study period. The treatment effect on the CAT score was 4.49 (95% CI: -8.41, -0.58) points lower in the myCOPD arm. Patients' inhaler technique improved in the digital intervention arm (101 improving to 20 critical errors) compared to usual care (100 to 72 critical errors). Exacerbations tended to be less frequent in the digital arm compared to usual care; 34 vs 18 events. Hospital readmissions risk was numerically lower in the digital intervention arm: OR for readmission 0.383 (95% CI: 0.074, 1.987; n = 35). In this feasibility study of the digital self-management platform myCOPD, the app has proven acceptable to patients to use and use has improved exacerbation recovery rates, with strong signals of lower re-exacerbation and readmission rates over 90 days. myCOPD reduced the number of critical errors in inhaler technique compared to usual care with written self-management. This provides a strong basis for further exploration of the use of app interventions in the context of recently hospitalised patients with COPD and informs the potential design of a large multi-centre trial.
Abstract 4958: A Novel Mouse Model of Thoracic Aortic Aneurysm Revealed the Protective Property of TNF-alpha Against the Rupture of Aneurysm
Authors: Hiroshi Iwata, Ichiro Manabe, Ryozo Nagai
Journal: Circulation (2009)

Despite high clinical frequencies, precise mechanism in development of aortic aneurysm and dissection remains largely unknown. We recently developed a novel mouse model of constantly producing thoracic aortic aneurysm. A nylon line (0.486mm in diameter) was inserted since the side-branch of femoral artery until the end reached the mid of thoracic aorta. The line was tied and placed in the artery. In wild-type mice, survival rate at 4 weeks after the procedure was 67% (28/42) and thoracic aorta aneurysm developed in 85% (26/28). Massive thoracic hemorrhage indicating aortic rupture was observed in 74% of dead mice (10/14). Proinflammatory genes such as TNF-alpha, MCP1 and IL6 were highly expressed in the aneurysm. Among them, TNF-alpha was constantly and highly expressed shortly (1 day) after the procedure, whereas peak transcriptional levels of other genes were observed at 2 weeks. As the unique temporal gene-expression pattern was observed, we performed this injury model to TNF-alpha-mutant mice. Surprisingly, Kaplan-Mayer analysis showed that survival rate in TNF-alpha-mutant mice was significantly lower in comparison with wild-type mice. 13 of 16 of mice (81%) died within 7 days and survival rate at 4 weeks was 0% (0/16). Histological analysis showed apparent hypocellularity around the injured aorta in TNF-alpha-mutant mice. These results suggest that TNF-alpha might play the role not only in accelerating vascular remodeling, but also in salvage from the aortic rupture in severe injured aorta by accumulating supporting cells.
Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)
Authors: Amer M. Zeidan, Victoria Wang, Jerald P. Radich, Jan Philipp Bewersdorf, Vijaya R. Bhatt, Elad Sharon, Steven D. Gore, Selina M. Luger, Mark Litzow
Journal: Blood (2020)
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
Authors: Paul Coppo, Michael Bubenheim, Elie Azoulay, Lionel Galicier, Sandrine Malot, Naïke Bigé, Pascale Poullin, François Provôt, Nihal Martis, Claire Presne, Olivier Moranne, Ruben Benainous, Antoine Dossier, Amélie Seguin, Miguel Hié, Alain Wynckel, Yahsou Delmas, Jean-François Augusto, Pierre Perez, Virginie Rieu, Christelle Barbet, François Lhote, Marc Ulrich, Anne Charvet Rumpler, Sten de Witte, Thierry Krummel, Agnès Veyradier, Ygal Benhamou
Journal: Blood (2020)